SMC recommends first targeted treatment for MZL
The first targeted treatment, zanubrutinib, is now available for people with relapsed or refractory MZL in Scotland.
News
New treatments and drug approvals
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
SMC recommends axicabtagene ciloleucel for DLCBL
New treatment available for relapsed or refractory DLBCL in Scotland.
NICE recommends first targeted treatment for MZL
The first targeted treatment zanubrutinib, is now available for people with marginal zone lymphoma
SMC recommends two new treatment options for DLBCL
Treatment recommended for patients with relapsed or refractory DLBCL who have had at least two other lines of treatment.
NICE recommends pembrolizumab for Hodgkin lymphoma
New treatment available for relapsed or refractory classical Hodgkin lymphoma.
New SMC guidance for DLBCL
The Scottish Medicines Consortium recommends loncastuximab tesirine but not axicabtagene ciloleucel as treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
NICE recommends Loncastuximab tesirine for DLBCL
New third line treatment available for relapsed or refractory diffuse large B-cell lymphoma.
NICE recommends glofitamab for DLBCL
New treatment available for relapsed or refractory diffuse large B-cell lymphoma.
Evusheld - Health Technology Assessment
A summary of our submission to the National Institute for Health Care and Excellence (NICE) for Evusheld.
Evusheld - update on 17 October 2022
Evusheld, the COVID-19 treatment which could prevent disease.